Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

423.24 +3.35 (+0.80%)
Streaming Delayed Price Updated: 11:03 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
What Does the Market Think About Vertex Pharmaceuticals Inc?
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 S&P 500 Stocks to Research Further and 1 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
5 Top Stocks to Buy in October
These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term. 
Via The Motley Fool
Topics Stocks
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts
Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. 
Via Benzinga
Vertex Announces Key Advancements Across Kidney Portfolio
From Vertex Pharmaceuticals Incorporated
Via Business Wire
This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
My 3 Favorite Stocks to Buy Right Now
Uncertainty is in the air. But these stocks inspire confidence. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top GARP Stock
Vertex Pharmaceuticals (VRTX) is a top GARP stock, offering strong revenue growth, high profitability, and a debt-free balance sheet at a reasonable valuation. 
Via Chartmill
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex... 
Via StockStory
Topics Artificial Intelligence
Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon
There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
From Vertex Pharmaceuticals
Via Business Wire
2 Growth Stocks to Buy and Hold Forever
Look beyond the recent headwinds these two have faced. 
Via The Motley Fool
Topics World Trade
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Screens as a Top Undervalued Stock with Strong Fundamentals
Vertex Pharmaceuticals (VRTX) is a strong value stock with high profitability, zero debt, and solid growth, trading at an attractive valuation within the biotech sector. 
Via Chartmill
Why This Biotech Company Could Be a Growth Stock Powerhouse
The stock has soared in the triple-digits over the past decade. 
Via The Motley Fool
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals
Here's why you can't find a Wall Street analyst who will tell you to sell this stock. 
Via The Motley Fool
Topics Intellectual Property
3 Absurdly Cheap Stocks to Buy for the Long Haul
They trade at some incredibly low earnings multiples. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
 
Via Benzinga
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Technical Breakout Potential
Vertex Pharmaceuticals (VRTX) is a top growth stock with strong fundamentals, high profitability, and a technical setup hinting at a potential breakout for investors. 
Via Chartmill
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
These companies are reaching key milestones. 
Via The Motley Fool
1 Safe-and-Steady Stock to Research Further and 2 We Turn Down
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Why This Biotech Company Could Be a Growth Stock Powerhouse
Recent developments aren't as devastating to the company's prospects as some might think. 
Via The Motley Fool
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
 
Via Benzinga
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Top GARP Stock with Strong Growth and Reasonable Valuation
Vertex Pharmaceuticals (VRTX) exemplifies the GARP strategy with strong growth, a reasonable valuation, high profitability, and a robust debt-free balance sheet. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.